Myelofibrosis other diagnostic studies

Revision as of 18:11, 4 January 2019 by Ssharfaei (talk | contribs)
Jump to navigation Jump to search

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis other diagnostic studies

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis other diagnostic studies

CDC on Myelofibrosis other diagnostic studies

Myelofibrosis other diagnostic studies in the news

Blogs on Myelofibrosis other diagnostic studies

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]Sujit Routray, M.D. [3]

Overview

Other diagnostic studies for myelofibrosis include genetic testing, which demonstrates JAK2V617F mutation, hybrid imaging, which demonstrates increased uptake of the radionuclides by the extramedullary hematopoietic foci, and bone scintigraphy and positron emission tomography (PET), both of which demonstrate fibrosis.

Other Diagnostic Studies

Genetic Testing

Bone Scintigraphy

Positron Emission Tomography (PET)

Hybrid Imaging

References

  1. Zhu JF, Liu Y, Liu P, Jia MF, Cheng J, Zhao L (August 2011). "[JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 19 (4): 916–20. PMID 21867614.
  2. Zhang SP, Li H, Lai RS (February 2015). "Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms". Oncol Lett. 9 (2): 735–738. doi:10.3892/ol.2014.2801. PMC 4301535. PMID 25624900.
  3. 3.0 3.1 Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ (October 2017). "Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET". J. Nucl. Med. 58 (10): 1603–1608. doi:10.2967/jnumed.116.188508. PMID 28360204.
  4. Pour MC, Simon-Corat Y, Horne T (April 2004). "Diffuse increased uptake on bone scan: super scan". Semin Nucl Med. 34 (2): 154–6. PMID 15031814.
  5. Agool A, Schot BW, Jager PL, Vellenga E (October 2006). "18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment". J. Nucl. Med. 47 (10): 1592–8. PMID 17015893.
  6. Ojeda-Uribe M, Morel O, Ungureanu C, Desterke C, Le Bousse-Kerdilès MC, Boulahdour H (September 2016). "Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients". Cancer Med. 5 (9): 2378–84. doi:10.1002/cam4.835. PMC 5055194. PMID 27518041.